Free Biopharma Daily Stock Updates - 06/30/21

$XBI $135.40 -0.40%

---

Want to access our searchable Catalyst Calendar of over 1,000 biotech stock events and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!

---

Covid Updates

$AVIR -12.0% Atea’s AT-527, an Oral Antiviral Drug Candidate, Reduces Viral Replication in Hospitalized Patients with COVID-19 in Phase 2 Interim Analysis source

$NVAX 1.60% Novavax Statement on Proof of Vaccination for Phase 3 Clinical Trial Participants source

$NVAX -1.60% Novavax Publishes Results of United Kingdom Phase 3 Clinical Trial in New England Journal of Medicine, Demonstrating High Levels of Efficacy of COVID-19 Vaccine source

Pipeline Updates

$UTHR +1.3% United Therapeutics Announces The Lancet Respiratory Medicine Publication Of Post-Hoc Analysis Of FVC Change From The Tyvaso® INCREASE Study source

$MDGL +0.0% Madrigal Pharmaceuticals Completes Enrollment of the 52 Week Liver Biopsy Patient Population in the Phase 3 MAESTRO-NASH Study of Resmetirom source

$LYRA -4.0% Lyra Therapeutics Announces Positive Topline Results Of Pharmacokinetic Study Of Lyr-210 In Patients With Chronic Rhinosinusitis source

$ALKS +1.0% Alkermes Presented New Data Analysis on Healthcare Resource Use Among Veterans With Alcohol Dependence source

$AXLA -0.50% Axcella Announces Initiation of EMMPOWER℠ Phase 2 Clinical Trial of AXA1665 source

$CYTK -6.30% Cytokinetics Announces Additional Results From Galactic-hf Presented At The European Society Of Cardiology Heart Failure 2021 source

$ARWR +1.60% Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-ANG3 for Treatment of Mixed Dyslipidemia source

$RFL +1.30% Rafael Pharmaceuticals to Present Pancreatic & Biliary Tract Cancer Data on CPI-613® (Devimistat) from its Multicenter, Randomized Phase 1b/2 Trials at the 2021 European Society of Medical Oncology World Gastrointestinal (GI) Congress source

$LGVN +1.50% Longeveron Announces Two Abstracts Accepted for Presentation at the Gerontological Society of America 2021 Annual Scientific Meeting source

$FBIO -1.40% Journey Medical Corporation Enters into a Definitive Agreement with Dr. Reddy’s Laboratories Ltd. to Develop and Commercialize DFD-29 for the Treatment of Rosacea source

$ALPN -1.0% Alpine Immune Sciences to Collaborate with Merck on Immuno-Oncology Study to Evaluate ALPN-202 in Combination with KEYTRUDA® (pembrolizumab) source

$VCNX +3.0% Vaccinex to Chair Panel Q&A Session and Present Poster at the XV European Meeting on Glial Cells in Health and Disease source

$ALLO +3.5% Allogene Therapeutics Granted FDA Fast Track Designation for ALLO-605, the First TurboCAR™ T Cell Therapy, for the Treatment of Relapsed/Refractory Multiple Myeloma source

$SLS -15.0% SELLAS Reports Promising Updated Clinical Data and Initial Immune Response Profiles from Ongoing Phase 1/2 Study of Galinpepimut-S (GPS) Combined with Keytruda for Treating WT1+ Advanced Ovarian Cancer source

$BSGM -6.3% BioSig Completes 1000 Patient Cases with its Signal Processing System for Electrophysiology source

$CVM -32.0% CEL-SCI to Conduct Investor Call Regarding Phase 3 Results Following Annual Shareholder Meeting on July 1, 2021 source

$PHAS +1.30% PhaseBio Pharmaceuticals to Present at the William Blair Biotech Focus Conference 2021 on July 15 source

$DCPH +-0.0% Deciphera Announces First Patient Treated in Phase 1 Study of DCC-3116 in Patients with Advanced or Metastatic Tumors with a Mutant RAS or RAF Gene source

$APLS -0.40% Apellis and Beam Therapeutics Enter Exclusive Research Collaboration to Apply Base Editing to Discover Novel Therapies for Complement-Driven Diseases source

Financial Updates

$XBIT +-0.0% XBiotech Announces Receipt of $75 Million from Sale of Antibody source

---

Posted by JM